What does the research say about GLP-1s and insulin resistance in women?

A 2025 meta-analysis of randomized controlled trials found that GLP-1 medications significantly reduced fasting insulin, post-glucose-tolerance-test glucose, and HOMA-IR, a standard insulin resistance measure, in women with chronic anovulation and insulin resistance, alongside reductions in BMI and waist circumference. The same research found significantly increased rates of nausea, vomiting, and dizziness. Longer-term data on glucose and lipid outcomes in this population is still limited, and researchers are explicit that more study is needed before drawing firm conclusions.

The insulin resistance and hormone health connection, explained simply

Insulin resistance is a common driver of irregular ovulation and cycle irregularity in women, and it often shows up alongside excess weight or obesity, a combination that compounds metabolic risk. When cells respond less efficiently to insulin, the body produces more of it, and that excess insulin is thought to contribute to irregular cycles and elevated androgen levels in women affected by this pattern. Mayo Clinic's overview of hormone-driven ovulatory conditions explains that insulin resistance is one of several factors that can contribute to irregular ovulation, alongside genetic and hormonal contributors.

What the newest research shows about GLP-1s and metabolic markers

A 2025 meta-analysis published in Scientific Reports evaluated GLP-1 medications against metformin and placebo in a population of women affected by chronic anovulation and insulin resistance. It found that GLP-1 therapy significantly reduced fasting insulin, post-glucose-tolerance-test glucose, and HOMA-IR, alongside reductions in BMI, waist circumference, and waist-to-hip ratio. A separate 2026 systematic review in Cureus, evaluating 18 randomized controlled trials in the same population, similarly found that insulin resistance improved significantly with GLP-1 use, though the effect on total testosterone levels was not significant.

The side effects nobody mentions upfront

The Scientific Reports meta-analysis also found significantly increased rates of nausea, vomiting, and dizziness with GLP-1 use in this population, a side-effect pattern worth knowing about before starting therapy or while weighing alternatives. This tracks with what's documented more broadly in GLP-1 research: delayed gastric emptying is one of the physiological mechanisms researchers point to when explaining these ongoing digestive symptoms.

"It's not a one-size-fits-all."

— Dr. Samantha Ess, ND, Naturopathic Doctor specializing in hormone health and fertility

Supporting insulin signaling and cycle regularity long-term

Whether or not GLP-1 therapy is part of your plan, Myo Chiro 40:1, formulated to support healthy hormone signaling and ovarian health, pairs a clinically studied 40:1 ratio of Myo-Inositol to D-Chiro-Inositol to support healthy hormone signaling, ovarian health, and menstrual cycle regularity.† D-Chiro-Inositol specifically is studied for its role in supporting healthy androgen function and ovarian hormone function.†

This is a research-attribution piece, not a claim that Myo Chiro 40:1 replicates GLP-1 effects. The two work through different mechanisms, and this formula is not for use during pregnancy. Many women also pair it with our organic fertility tea with vitex and red raspberry leaf during the preconception and cycle-regularity window.† Fertility Tea is likewise not for use during pregnancy, and both require a provider consultation disclaimer before use while breastfeeding.

What this means if you're not on a GLP-1 (or come off one)

• Insulin resistance tied to irregular ovulation can be addressed through multiple pathways, not just one medication class
• Cycle regularity and hormone signaling support can be a foundational piece regardless of GLP-1 status
• Longer-term outcome data in this population is still developing, so treatment plans should stay individualized
• Side effect profiles matter just as much as efficacy data when weighing any option with your provider

If you're specifically navigating a GLP-1 taper as part of preconception planning, the current OB/GYN guidance on timing and discontinuation is a useful next read, and rebound digestive symptoms are common enough to deserve their own explanation.

"Every woman's body tells its own story, and hormone health looks different from one woman to the next. We believe in giving you real information and real support, so you can make decisions rooted in both faith and science."

— Amy Suzanne Upchurch, Founder and CEO of Pink Stork

Myo Chiro 40:1 uses a clinically studied ratio, is third-party tested, and is made in cGMP-certified facilities.

Frequently asked questions

What causes insulin resistance to affect ovulation?

Excess insulin is thought to contribute to irregular cycles and elevated androgen levels in women affected by this pattern, which is why insulin resistance and cycle irregularity often show up together.

Do GLP-1 medications treat hormone-driven insulin resistance?

GLP-1 medications are not approved specifically to treat any named condition. Research has studied their effect on metabolic markers like insulin resistance and BMI in women affected by this pattern, with promising but still-developing results.

What are the most common side effects of GLP-1 therapy for this population?

Research has found significantly increased rates of nausea, vomiting, and dizziness with GLP-1 use, alongside the metabolic improvements.

Does GLP-1 use lower testosterone in women with insulin resistance?

A 2026 systematic review found no significant effect on total testosterone levels, even as insulin resistance and BMI improved, so androgen-related symptoms may not respond the same way as metabolic markers.

What is Myo Chiro 40:1 used for?

Myo Chiro 40:1 is a clinically studied 40:1 ratio of Myo-Inositol to D-Chiro-Inositol formulated to support hormonal wellness, ovarian health, and menstrual cycle regularity.†

Can I take Myo Chiro 40:1 alongside a GLP-1 medication?

This is a conversation for your provider. Myo Chiro 40:1 has no known interaction with GLP-1 medications, but any combination of a supplement and a prescription medication should be reviewed with your healthcare provider.

† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting any new supplement, especially during pregnancy, breastfeeding, or while managing a medical condition. Keep out of reach of children.